🎉 M&A multiples are live!
Check it out!

Kymera Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Kymera Therapeutics and similar public comparables like Vivoryon Therapeutics, Julphar, and Galapagos.

Kymera Therapeutics Overview

About Kymera Therapeutics

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.


Founded

2015

HQ

United States of America
Employees

188

Website

kymeratx.com

Financials

LTM Revenue $49.0M

LTM EBITDA -$274M

EV

$1.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Kymera Therapeutics Financials

Kymera Therapeutics has a last 12-month revenue of $49.0M and a last 12-month EBITDA of -$274M.

In the most recent fiscal year, Kymera Therapeutics achieved revenue of $47.1M and an EBITDA of -$216M.

Kymera Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Kymera Therapeutics valuation multiples based on analyst estimates

Kymera Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $78.6M $47.1M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$143M -$216M XXX XXX XXX
EBITDA Margin -182% -459% XXX XXX XXX
Net Profit -$155M -$147M XXX XXX XXX
Net Margin -197% -312% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Kymera Therapeutics Stock Performance

As of April 15, 2025, Kymera Therapeutics's stock price is $25.

Kymera Therapeutics has current market cap of $1.7B, and EV of $1.3B.

See Kymera Therapeutics trading valuation data

Kymera Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.3B $1.7B XXX XXX XXX XXX $-3.19

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Kymera Therapeutics Valuation Multiples

As of April 15, 2025, Kymera Therapeutics has market cap of $1.7B and EV of $1.3B.

Kymera Therapeutics's trades at 25.5x LTM EV/Revenue multiple, and -4.6x LTM EBITDA.

Analysts estimate Kymera Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Kymera Therapeutics and 10K+ public comps

Kymera Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.3B XXX XXX XXX
EV/Revenue 26.6x XXX XXX XXX
EV/EBITDA -5.8x XXX XXX XXX
P/E -7.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -6.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Kymera Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Kymera Therapeutics Valuation Multiples

Kymera Therapeutics's NTM/LTM revenue growth is 18%

Kymera Therapeutics's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $1.6M for the same period.

Over next 12 months, Kymera Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Kymera Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Kymera Therapeutics and other 10K+ public comps

Kymera Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -40% XXX XXX XXX XXX
EBITDA Margin -459% XXX XXX XXX XXX
EBITDA Growth 51% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -442% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $1.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 135% XXX XXX XXX XXX
R&D Expenses to Revenue 510% XXX XXX XXX XXX
Opex to Revenue 645% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Kymera Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Kymera Therapeutics M&A and Investment Activity

Kymera Therapeutics acquired  XXX companies to date.

Last acquisition by Kymera Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Kymera Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Kymera Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Kymera Therapeutics

When was Kymera Therapeutics founded? Kymera Therapeutics was founded in 2015.
Where is Kymera Therapeutics headquartered? Kymera Therapeutics is headquartered in United States of America.
How many employees does Kymera Therapeutics have? As of today, Kymera Therapeutics has 188 employees.
Who is the CEO of Kymera Therapeutics? Kymera Therapeutics's CEO is Dr. Nello Mainolfi, PhD.
Is Kymera Therapeutics publicy listed? Yes, Kymera Therapeutics is a public company listed on NAS.
What is the stock symbol of Kymera Therapeutics? Kymera Therapeutics trades under KYMR ticker.
When did Kymera Therapeutics go public? Kymera Therapeutics went public in 2020.
Who are competitors of Kymera Therapeutics? Similar companies to Kymera Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Kymera Therapeutics? Kymera Therapeutics's current market cap is $1.7B
What is the current revenue of Kymera Therapeutics? Kymera Therapeutics's last 12-month revenue is $49.0M.
What is the current EBITDA of Kymera Therapeutics? Kymera Therapeutics's last 12-month EBITDA is -$274M.
What is the current EV/Revenue multiple of Kymera Therapeutics? Current revenue multiple of Kymera Therapeutics is 25.5x.
What is the current EV/EBITDA multiple of Kymera Therapeutics? Current EBITDA multiple of Kymera Therapeutics is -4.6x.
What is the current revenue growth of Kymera Therapeutics? Kymera Therapeutics revenue growth between 2023 and 2024 was -40%.
Is Kymera Therapeutics profitable? Yes, Kymera Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.